A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).

Trial Details

NCT ID
NCT06232096
Phase
PHASE1 / PHASE2
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • MBS314 Injection
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Able and willing to provide written informed consent and to comply with the study protocol;
  • ≥18 years of age;
  • Documented diagnosis of multiple myeloma according to 2014 IMWG diagnostic criteria.
  • Phase Ⅰb/Ⅱ: At least one measurable disease: Serum monoclonal paraprotein (M-protein) ≥5 g/L or Urine M-protein ≥200 mg/24 hours or Serum immunoglo…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →